Uncu Ulu, B. Et Al. 2022. Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients. Journal of Chemotherapy , vol.34, no.3 , 190-198.

Uncu Ulu, B., Dal, M. S., Yönal Hindilerden, İ., Akay, O. M., MEHTAP, Ö., Büyükkurt, N., ... Hindilerden, F.(2022). Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients. Journal of Chemotherapy , vol.34, no.3, 190-198.

Uncu Ulu, Bahar Et Al. "Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients," Journal of Chemotherapy , vol.34, no.3, 190-198, 2022

Uncu Ulu, Bahar U. Et Al. "Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients." Journal of Chemotherapy , vol.34, no.3, pp.190-198, 2022

Uncu Ulu, B. Et Al. (2022) . "Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients." Journal of Chemotherapy , vol.34, no.3, pp.190-198.

@article{article, author={Bahar Uncu Ulu Et Al. }, title={Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients}, journal={Journal of Chemotherapy}, year=2022, pages={190-198} }